The Association of the British Pharmaceutical Industry (ABPI) and the Department of Health (DH) have today published a joint DH/ABPI statement on arrangements for pricing branded medicines from 2014.
The joint statement sets out the areas where we already have clarity and identifies a number of points and principles which will need to be taken into account in the new arrangements.
The negotiations, which are set to begin in September, will determine the arrangements for pricing branded medicines in the UK from 2014, including medicines that are already on the market in December 2013 and new medicines which are launched from 1 January 2014.
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441 Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064Email: email@example.com
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.